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ABSTRACT
Epigenetic mechanisms can mediate gene-environment interactions relevant for complex disorders. The
BDNF gene is crucial for development and brain plasticity, is sensitive to environmental stressors, such as
hypoxia, and harbors the functional SNP rs6265 (Val66Met), which creates or abolishes a CpG dinucleotide
for DNA methylation. We found that methylation at the BDNF rs6265 Val allele in peripheral blood of
healthy subjects is associated with hypoxia-related early life events (hOCs) and intermediate phenotypes
for schizophrenia in a distinctive manner, depending on rs6265 genotype: in ValVal individuals increased
methylation is associated with exposure to hOCs and impaired working memory (WM) accuracy, while the
opposite is true for ValMet subjects. Also, rs6265 methylation and hOCs interact in modulating WM-related
prefrontal activity, another intermediate phenotype for schizophrenia, with an analogous opposite
direction in the 2 genotypes. Consistently, rs6265 methylation has a different association with
schizophrenia risk in ValVals and ValMets. The relationships of methylation with BDNF levels and of
genotype with BHLHB2 binding likely contribute to these opposite effects of methylation. We conclude
that BDNF rs6265 methylation interacts with genotype to bridge early environmental exposures to adult
phenotypes, relevant for schizophrenia. The study of epigenetic changes in regions containing genetic
variation relevant for human diseases may have beneficial implications for the understanding of how
genes are actually translated into phenotypes.
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Introduction
Differentially methylated regions often contain single nucleo-
tide polymorphisms (SNPs) critical for human diseases.1 CpG
methylation state is recognized as a major determinant of natu-
ral genetic variation,2 and a strong genetic component under-
lies inter-individual variation in DNA-methylation profiles.3
While it has been argued that many SNPs contribute to gene-
expression changes and phenotypes relevant for diseases via
epigenetic mechanisms,3,4 the possibility that DNA methylation
changes may compensate and/or modulate the effect of genetic
variation has been less studied. Such event may be important in
reconciling variable penetrance of genetic variants associated
with human diseases. Our research has previously approached
this issue by analyzing variable methylation of CpGs associated
with functional SNPs, which likely originate during evolution
from spontaneous point mutation of 5-methyl-cytosine into
thymine. Specifically, we previously reported that methylation
of a CpG created by a widely studied functional SNP in the
COMT gene was sensitive to environmental experience and
associated with brain phenotypes only in individuals homozy-
gous for the ancestral allele, but no association was found in
heterozygotes.5
In the present work we focus our analysis on another
popular gene in behavioral genetics, highly important in
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neurodevelopment and in system-level neural phenotypes and
sensitive to environmental factors, the gene coding for the
Brain Derived Neurotrophic Factor (BDNF). BDNF is a highly
regulated protein, a crucial factor for the development of the
feto-placental unit6 and of the brain,7 as well as for neural plas-
ticity, energy metabolism, learning, episodic and working mem-
ory (WM) 7–12 and cancer.13 The effects of BDNF on synaptic
plasticity and neuron survival strongly suggest a role for this
factor in schizophrenia, a neurodevelopmental disorder whose
risk is heritable and characterized by physiological prefrontal
cortex (PFC) dysfunction during WM,14–16 as well as reduced
prefrontal levels of BDNF.17 However, BDNF has not been
associated with schizophrenia in recent large scale genome
wide association studies.18 BDNF expression is sensitive to
early-life environment19–21 and specifically hypoxic-stres-
sors,22,23 which, in turn, are critical factors involved in the path-
ophysiology of schizophrenia.24–27 The failure to find
association between BDNF and schizophrenia in large-scale
case control studies may conceivably reflect a complex interac-
tion of genotype and environmental experience that alters
methylation status.
The SNP rs6265 (G> A, Val66Met), in the human Pro-BDNF
sequence, is an example of a well-characterized functional SNP in
this gene, which influences intracellular trafficking, activity-
dependent secretion, as well as memory related behavior and
brain activity in transgenic mice and in humans.8–11 However,
while cell and animal models are consistent in showing a func-
tional effect, studies in humans reveal discrepancies in associating
the Met or the Val allele to phenotypes relevant for schizophrenia
and different psychiatric disorders.8–10,28–33 Interestingly, hyp-
oxia-related events during pre-, peri- and early post-natal life
(hOCs) have been reported to interact with BDNF in affecting
risk for schizophrenia, independently from rs6265. Specifically,
birth hypoxia has been associated with reduced BDNF levels in
cord samples, taken at delivery, of individuals who developed
schizophrenia later in life,34 and other genetic variation of the
BDNF signaling interact with early life hypoxia in affecting risk
for the disorder.35 Surprisingly, these studies failed to show a role
of rs6265 in interacting with obstetric complications in affecting
risk for schizophrenia. A possible explanation for these results is
that epigenetic mechanisms related to these environmental fac-
tors modulate the effect of the most likely relevant functional
SNP of BDNF. Indeed, the G>A (Val>Met) substitution of the
rs6265 SNP creates/abolishes a CpG site, so that the Val allele has
a CpG at this position while the Met allele does not. Since this
CpG is differentially methylated in humans,36 we hypothesize
that the epigenetic changes able to modulate the effect of rs6265
may correspond to a different methylation status of the Val allele
in ValVals and ValMets. In other words, while in experimental
models the rs6265 genotype is clearly associated with certain out-
comes, in living people who experience actual life and its many
stressors DNA methylation specifically of one allele of this SNP
may change in response to those factors, such as hOCs, and may
modulate specific phenotypes, thus weakening the effect of the
rs6265 genotype.
We hypothesize that BDNF rs6265 methylation is sensitive
to environmental (hOCs) exposure both in ValVal and ValMet
subjects and is also associated with phenotypes relevant for
schizophrenia. To this purpose, we analyze (Fig. 1):
1. the interaction between hOCs exposure, a known risk
factor for schizophrenia, BDNF rs6265 genotype and
methylation in blood;
2. the interaction between hOCs exposure, BDNF rs6265
genotype and methylation on intermediate phenotypes
of schizophrenia, i.e., working memory performance and
related neural activity measured with fMRI;
3. the heritability of rs6265 methylation and the interaction
between BDNF rs6265 genotype and methylation on
genetic risk for schizophrenia;
4. the interaction between BDNF rs6265 genotype and
methylation on serum BDNF levels, which are known to
be altered in patients with schizophrenia;
5. the relationship between brain and blood methylation in
a sample of transgenic mice;
6. the effect of the rs6265 genetic variation on DNA-protein
binding, potentially relevant in explaining the relation-
ship between methylation and BDNF levels.
We found that hOCs exposure is associated with opposite
methylation changes in ValVal and ValMet subjects. These
methylation changes are associated with intermediate pheno-
types of schizophrenia and being partially inherited predict
genetic risk for the disorder, differently in ValVals and Val-
Mets. Moreover, the rs6265 genotype affects binding of the
transcription factor BHLHB2, potentially explaining the oppo-
site relationship between methylation and serum BDNF levels
that we detected in ValVals and ValMets. The correlation
between brain and blood methylation in mice further supports
the possibility of using peripheral methylation as a proxy of
epigenetic changes relevant for the brain.
Results and discussion
Relationship between rs6265 genotype, methylation and
hypoxia-related complications (hOCs)
Given that brain methylation cannot be studied in vivo in
humans, and that epigenetic changes relevant for developmen-
tal programming can be part of a general response of the entire
organism,20,37 we used pyrosequencing to analyze rs6265 meth-
ylation in peripheral blood mononuclear cells (PBMCs) of 259
healthy humans. This site is differentially methylated in human
PBMCs and, as predictable, methylation was affected by rs6265
genotype, given that only the Val allele has a CpG in this posi-
tion (ANOVA: ND259; F2,256D1601.2; P < 0.001; ValVal >
ValMet >MetMet; Fig. S1). ValVal subjects have greater meth-
ylation compared with ValMets, while MetMet subjects have
no methylation. All analyses were therefore performed only in
ValVal and ValMet individuals, and methylation values were
normalized in order to test for interactions between genotype
and methylation.
First, we analyzed in living healthy humans whether BDNF
rs6265 methylation in PBMCs is associated with exposure to
hypoxia-related events during prenatal, perinatal, and early
postnatal life (hOCs), a known risk factor for schizophrenia.
Using the McNeil-Sj€ostr€om Scale,35 we assessed exposure to
hOCs in 168 healthy humans demonstrating that the relation-
ship between hOCs exposure and BDNF rs6265 methylation is
affected by rs6265 genotype. In fact, we found an interaction
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Figure 1. Research design.
Figure 2. Relationship between methylation of BDNF rs6265 in PBMCs and hOCs exposure in healthy humans. Boxplot of rs6265 methylation (T scores) as a function of
hOCs exposure: Val/Val homozygotes (N D 110) exposed to hOCs have greater methylation compared with ValVal not exposed, while Val/Met subjects (N D 59) exposed
have reduced methylation compared with ValMet not exposed. See text and Supplemental file 1 for statistics.
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between rs6265 genotype and hOCs on methylation (Factorial
ANCOVA, with age and sex as covariates: N D 169: 110
ValVal, 59 ValMet; F5,163 D 9.70; P D 0.002; Fig. 2), so that
rs6265 methylation is greater in the presence of hOCs in ValVal
homozygotes (P D 0.03), while it is attenuated in ValMet sub-
jects exposed to hOCs (P < 0.02; see Supplemental file 1 for
detailed results). On the other hand, BDNF rs6265 methylation
was not associated with age and sex, in the whole sample, and
in the 2 genotype groups (P > 0.28). These results suggest that
exposure to hOCs is associated with opposite and long-lasting
changes of rs6265 methylation in ValVal and in ValMet
subjects.
Relationship between rs6265 genotype, methylation,
hOCs, and intermediate phenotypes for schizophrenia
We then analyzed the relevance of these methylation changes
for schizophrenia. Since we found that rs6265 methylation is
related with hOCs which are a risk factor for schizophrenia,25,35
we assessed the relationship between hOCs exposure, BDNF
rs6265 genotype and methylation in PBMCs, and WM perfor-
mance and related prefrontal activity, 2 well established inter-
mediate phenotypes for this neurodevelopmental disorder.15
Consistent with the above results, we found that, in a sample of
212 healthy humans, BDNF rs6265 methylation is correlated
with 2-back WM performance both in ValVal and ValMet sub-
jects with a qualitatively different direction. More in details, a
multiple regression of BDNF rs6265 genotype, methylation and
hOCs and their interactions, with 2-back WM accuracy as the
dependent variable (age and sex as covariates), revealed an
interaction between rs6265 genotype and methylation on WM
performance (N D 211: 145 ValVal, 66 ValMet; t D 2.63,
P D 0.009; Fig. 3), so that BDNF rs6265 methylation is associ-
ated with 2-back WM performance both in ValVal and ValMet
subjects with a qualitatively different direction; consistent with
previous studies,8,38 this analysis also confirmed lower WM
performance in ValMet compared with ValVal (t D ¡2.51,
P D 0.01). Post-hoc analyses of the interaction indicated that
greater methylation is associated with lower accuracy in ValVal
homozygous (t D ¡2.46, P D 0.01), while the opposite is
found in ValMet (t D 2.55, P D 0.01; Fig. 3; see Supplemental
file 1 for detailed results). Taken together, these results suggest
that the relationship between methylation of the Val allele and
WM performance is opposite between the 2 genotype groups.
However, the opposite methylation changes associated in ValV-
als (increased methylation) and ValMets (blunted methylation)
with hOCs exposure were similarly associated with decreased
WM accuracy.
We also analyzed the potential relationship between rs6265
genotype, methylation, hOCs, and prefrontal activity during
WM measured with fMRI, another intermediate phenotype of
schizophrenia, in a group of 141 healthy subjects who under-
went fMRI during the N-back task (Fig. 4A-E). Multiple regres-
sion of the imaging data in SPM8 demonstrated: a positive
correlation between BDNF rs6265 genotype and left dorsolat-
eral PFC activity during 2-back, suggesting greater activity
in ValMet subjects compared with ValVal (N D 141: 93 ValVal,
48 ValMet; x D ¡54, y D 24, z D 32, BA46, k D 31, Z D 3.42,
pFWE-corrected D 0.027); a positive correlation between BDNF
rs6265 methylation and left prefrontal activity (x D ¡54,
y D 24, z D 32, BA46, k D 31, Z D 3.29, pFWE-corrected D 0.041);
an interaction between BDNF rs6265 genotype, methylation,
and hypoxia exposure on left prefrontal activity (Fig. 4A).
More specifically, in one prefrontal locale, greater methylation
is associated with attenuated prefrontal activity in subjects
exposed to hypoxia compared with subjects not exposed in
the context of ValVal genotype but not in ValMet subjects
(x D ¡54, y D 24, z D 32, BA46, k D 26, Z D 3.24, pFWE-corrected
D 0.047; Fig. 4B-C; difference test between ValVal subjects
with and without hypoxia exposure: Z D 2.38, P D 0.008). On
the contrary, in the other prefrontal locale, lower methylation
is associated with attenuated prefrontal activity in subjects with
Figure 3. Relationship between methylation of BDNF rs6265 in PBMCs and working memory (WM) accuracy in healthy subjects. Scatterplot of the correlations between
methylation of rs6265 (T scores) and WM accuracy: in Val/Val subjects (N D 145) increased methylation is associated with impaired accuracy, while in Val/Met heterozy-
gotes (N D 66) blunted methylation is associated with impaired accuracy (See text and Supplemental file 1 for statistics).
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hOCs compared with subjects without hypoxia exposure in
the context of ValMet genotype but not in ValVal subjects
(x D ¡54, y D 32, z D 6, BA46, k D 14, Z D 3.40,
pFWE-corrected D 0.044; Fig. 4D-E; Difference test between Val-
Met subjects with and without hypoxia exposure: Z D ¡2.32,
P D 0.01). These results suggest that prefrontal activity during
WM is predicted by the interaction of hOCs exposure and
methylation to describe opposite relationships in ValVal and
ValMet subjects. Since attenuated prefrontal activity for equiva-
lent gains in WM accuracy is considered indicative of increased
efficiency of prefrontal cortex,14,39,40 the opposite methylation
changes associated with hOCs exposure in the 2 genotypes
(increased methylation in ValVal and blunted methylation in
ValMets) were also associated with increased activity, i.e.,
impaired prefrontal efficiency, which represents a phenotype
characteristic of patients with schizophrenia and their
relatives.14,39,40
Relationship between BDNF rs6265 genotype, methylation
and genetic risk for schizophrenia
We further investigated whether BDNF rs6265 methylation can
be inherited and is associated with genetic risk for schizophre-
nia. We analyzed BDNF rs6265 methylation in a sample of fam-
ilies with schizophrenia and we calculated heritability from the
regression slope of offspring methylation on the average meth-
ylation of parents. Interestingly, we estimated in a cohort of
115 families that BDNF rs6265 methylation is not only sensitive
to environmental exposures but can also be partially inherited
(h2 D 0.2; Fig. S2). Next, we analyzed whether rs6265 genotype
and methylation interact on risk for schizophrenia, by compar-
ing healthy subjects with patients with schizophrenia, with sib-
lings and with parents of patients in 3 separate analyses.
Consistent with the above results, we found an interaction
between rs6265 genotype and methylation on schizophrenia
risk, when comparing healthy subjects whether with siblings
(N D 384, F5,378 D 10.39, P D 0.001), or with parents
(N D 461, F5,455 D 9.47, P D 0.002) or with patients with
schizophrenia (N D 406, F5,400 D 4.01, P D 0.04; Fig. 5A; Sup-
plemental file 1). Specifically, rs6265 methylation in ValVal
subjects is lower in healthy subjects, compared with siblings
(post hoc with Tukey HSD: P D 0.01), parents (P D 0.02) and
patients (P < 0.01), so that in ValVal the methylation
changes associated with hypoxia are also associated with
schizophrenia risk. We also found a significant association
between BDNF rs6265 methylation and schizophrenia risk in
ValMet subjects. In this case, healthy subjects have greater
methylation compared with siblings (P D 0.03) and parents of
patients (P D 0.02), so that also in ValMets the methylation
changes associated with hypoxia are associated with schizo-
phrenia risk. However, ValMet patients are not significantly
different from healthy subjects (P D 0.79). Since we cannot
exclude that these effects may have been confounded by treat-
ment with antipsychotics which alter BDNF levels in patients,21
we also evaluated in vitro the potential effect of treatment with
haloperidol 1 mM for 2 and 5 hours on rs6265 methylation, in
Figure 4. Interaction between BDNF rs6265 genotype, methylation in PBMCs, early life exposure to hypoxia (hOCs), and prefrontal activity during working memory (WM)
in healthy subjects. a: 3D rendering of the interaction between rs6265 genotype, methylation and hOCs on BOLD fMRI response in prefrontal cortex of ValVal (N D 93)
and ValMet (N D 48) subjects. Color bar represents F-values. b-c: Scatterplots of the interaction in BA 46 (x D ¡54, y D 24, z D 32) showing that increased methylation is
associated with attenuated prefrontal activity in ValVal subjects exposed to hypoxia (B), while no significant relationship emerged in ValMet subjects (C). d-e: Scatterplots
of the interaction in BA 46 (x D ¡54, y D 32, z D 6) showing that methylation is positively associated with prefrontal activity in ValMet subjects exposed to hypoxia (E),
while no significant relationship emerged in ValVal subjects (D). See text for statistics.
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PBMCs of ValVal and ValMet healthy subjects (Fig. 5B). Nota-
bly, rs6265 genotype and haloperidol treatment interact on
methylation, so that haloperidol significantly increases BDNF
rs6265 methylation in ValMet subjects, but it does not in
ValVal (N D 17, 11 ValVal and 6 ValMet; Factorial ANOVA:
F2,44 D 5.65, P D 0.006; post hoc with Tukey HSD: “ValVal
basal” vs. “ValVal Haloperidol 2 h”, P D 0.8; “ValVal basal” vs.
“ValVal Haloperidol 5 h”, P D 1, “ValVal Haloperidol 2 h” vs.
“ValVal Haloperidol 5 h”, P D 0.9; “ValMet basal” < “ValMet
Haloperidol 2 h”, P D 0.02; “ValMet basal” < “ValMet Halo-
peridol 5 h”, P D 0.002, “ValMet Haloperidol 2 h” vs. “Val-
Met Haloperidol 5 h”, P D 0.92; Fig. 5B). These results suggest
that greater levels of methylation in ValMet patients may be
related to antipsychotic treatment (Fig. 5B), although further
experiments are necessary to address the effect of chronic expo-
sure to this and other antipsychotics on DNA methylation.
Moreover, since information on hOCs exposure were not avail-
able in our sample of families with schizophrenia, we cannot
exclude that the levels of methylation in patients, parents and
siblings were also related to these or other risk factors. How-
ever, the comparison of rs6265 methylation levels of controls
with methylation of parents and siblings of patients, in the con-
text of ValVal and ValMet genotype, indicates that the relation-
ship between methylation of the Val allele and genetic risk for
schizophrenia is opposite between the 2 genotype groups.
Therefore, our data show that methylation changes in the
rs6265 region are associated with hOCs exposure, WM accu-
racy and related prefrontal activity, and genetic risk for schizo-
phrenia, in a distinctive manner, depending on the rs6265
genotype. Specifically, in individuals with the ValVal genotype
hOCs exposure is associated with increased methylation, and
enhanced methylation—in these individuals—means impaired
WM accuracy, increased prefrontal activity during fMRI (i.e.,
blunted prefrontal efficiency) and increased genetic risk for
schizophrenia. On the other hand, in ValMet subjects the same
insult is associated with decreased methylation, but blunted
methylation turns out to be associated, in this genotype, with,
again, impaired WM accuracy and increased genetic risk for
schizophrenia.
Relationship between rs6265 genotype, methylation and
BDNF levels in serum
To be able to attribute any potential relevance to methylation
changes it is essential to assess their relationship with gene
expression. Thereby, we analyzed the relationship between
rs6265 methylation and serum BDNF levels measured with
ELISA in a subsample of healthy subjects.41 A multiple regres-
sion, with BDNF levels as dependent variable and BDNF
rs6265 genotype and methylation as predictors, revealed a sig-
nificant interaction between rs6265 genotype and methylation
on total BDNF expression in serum (N D 39: 23 ValVal, 16
ValMet; t D 4.37, P < 0.001; Fig. 6A). Specifically, greater
methylation is associated with greater levels of BDNF in ValVal
subjects (t D 3.04, P < 0.01), while this relationship is oppo-
site in ValMet subjects (t D -3; P D 0.01). Univariate results
also indicate an effect of rs6265 genotype on BDNF levels,
which are greater in ValMet compared with ValVal subjects (t
D 4.3; P< 0.001; see Supplemental file 1 for detailed results).
On the other hand, we did not detect a significant relation-
ship between BDNF rs6265 methylation and mRNA expression
in PBMCs (P < 0.2, not shown). This may raise the concern
that BDNF rs6265 methylation represents something indirectly
associated with schizophrenia, rather than a risk factor. How-
ever, since the expression of BDNF mRNA does not reflect the
rate of protein synthesized,42 the relationship of BDNF rs6265
methylation with BDNF protein level may also be the result of
the contribution of other elements, such as the expression of
non-coding transcripts, affecting the level of BDNF protein by
acting at a post-transcriptional level.43,44 Moreover, since
human platelets represent a main source of serum BDNF pro-
tein but not of BDNFmRNA, serum BDNF has been postulated
not to originate from megakaryocyte precursor cells, while
potential sources include CNS41,45,46; indeed, it has been shown
that BDNF can readily cross the brain-blood barrier.47 The
relationship between rs6265 methylation in PBMCs and serum
BDNF levels is therefore compatible with a potential link
between rs6265 methylation in PBMCs and in brain.
Figure 5. BDNF rs6265 methylation in PBMCs and schizophrenia risk. a: Bargraph
(mean § s.e.m.) of rs6265 methylation (T scores) in healthy subjects (168 ValVal,
77 ValMet), patients with schizophrenia (122 ValVal, 40 ValMet), siblings (97 ValVal,
43 ValMet), parents of patients (148 ValVal, 69 ValMet): in ValVal subjects, rs6265
methylation is lower in healthy subjects, compared with siblings, parents and
patients with schizophrenia. In ValMet subjects, rs6265 methylation is greater in
healthy subjects, compared with siblings and parents of patients, while it is not sig-
nificantly different compared with patients. b: Bargraph (mean C s.e.m.) of the
effect of treatment with haloperidol 1 mM for 2 and 5 hours on rs6265 methylation
changes in PBMCs of ValVal (N D 11) and ValMets (N D 6). See text and Supple-
mental file 1 for statistics.
16 G. URSINI ET AL.
Relationship between brain and blood BDNF methylation
in mice
We estimated the relationship between BDNF rs6265 methyla-
tion in PBMCs and in brain in transgenic mice carrying the
human rs6265 SNP and the analysis revealed a negative correla-
tion between PFC and PBMCs methylation – greater PFC
methylation of the rs6265 Val allele is correlated with lower
methylation in PBMCs of both ValVal mice (N D 7; Rho D
¡0.78 ; P D 0.04; Fig. S3A) and ValMet mice (N D 9; Rho D
¡0.8 ; P D 0.01; Fig. S3B). Similarly, the correlation between
PFC and PBMCs methylation of a CpG close to rs6265 (hg19
position: Chr11: 27,679,922-3) is negative in the whole sample
(N D 17; Rho D ¡0.55 ; P D 0.02; Fig. 6B). These results imply
that methylation in PBMCs can also be used as a peripheral
proxy of PFC methylation of rs6265, although the direction of
the correlations demonstrated above may be reversed when
considering rs6265 methylation in PFC. However, further stud-
ies are necessary to evaluate whether the relationship between
rs6265 methylation in PBMCs and phenotypes relevant for
schizophrenia is related to brain-blood correlation of methyla-
tion levels or is simply due to rs6265 methylation in PBMCs
being an “epigenetic fossil” that keeps trace of early events rele-
vant for brain development.
Relationship between rs6265 genotype and DNA-protein
binding
Since a differential effect of methylation can be mediated by
direct interference with DNA-protein binding,48 which can be
affected by genotype-specific changes,49 we next addressed the
potential relationship between BDNF rs6265 genotype and pro-
tein/transcription factors (TFs) binding. The rs6265 region,
identified as a DNAse I hypersensitive site in brain,50 is poten-
tially interesting for the binding of TFs, since the Val allele
shows putative binding sites for HIF1a, BHLHB2 (also known
as DEC1 or BHLHE40), and CREB. These sites are disrupted
by the G(Val)/A(Met) substitution, which also creates a binding
site for MITF on the Met allele. Previous studies have shown
how the interaction between all these factors is complex and
likely involves BDNF, the demethylating protein GADD45B,
and hypoxia-related mechanisms. For example, binding of
CREB51 and GADD45B52 in the BDNF region upstream of the
rs6265 SNP has been detected. Moreover, BHLHB2 and
GADD45B are regulated by hypoxia, since they have a high-
stringency HIF1 binding site,53,54 and BHLHB2 represses
expression of MITF,53 a TF stimulating HIF1a expression.55
Studies in mice have also proved how the basic helix-loop-helix
protein BHLHB2 is regulated by neurotrophins and modulate
BDNF transcription.56 As a consequence, we performed an
experiment of chromatin immunoprecipitation (ChIP), with
the aim of verifying whether these proteins and TFs related to
hypoxia could bind the Val allele in the rs6265 region, poten-
tially interacting in a different way in ValVal and ValMet sub-
jects. Our data confirmed that this region may bind
GADD45B, HIF1a, BHLHB2, CREB, and MITF (Fig. 6C,
detailed results in Supplemental file1). In addition, ANOVA
showed that BDNF rs6265 genotype was associated with differ-
ential binding of BHLHB2, which was greater in the context of
ValMet genotype, compared with the ValVal (N D 20: 11
ValVal and 9 ValMet; F1,18 D 5.71; P D 0.02; Fig. 6C). Other
TFs showed a similar trend, without reaching statistical signifi-
cance for the differential binding in ValVals and ValMets. In
addition, the greater binding of MITF in ValMets compared
with ValVals is likely less relevant, since the putative binding
site for this TF is present only on the Met allele.
All these findings indicate that rs6265 methylation of the
BDNF Val allele has a differential relationship with BDNF lev-
els and environmental exposures in ValVal and ValMet sub-
jects, likely through a different interaction with transcription
Figure 6. BDNF rs6265 methylation and gene regulation. a: Scatterplots of the cor-
relations between rs6265 methylation (T scores) and Total BDNF in serum mea-
sured with ELISA (N D 39: 23 ValVal and 16 ValMet): increased methylation in
PBMCs is correlated with increased expression in ValVal subjects and with attenu-
ated expression in ValMet heterozygotes. b: Scatterplot of the correlation between
methylation of rs6265 region in PBMCs and in prefrontal cortex in a group of trans-
genic mice carrying the human mutation (N D 17). c: Bargraph (mean C s.e.m.) of
the effects of rs6265 genotype on binding of hypoxia-related proteins to the
rs6265 region (N D 20: 11 ValVal and 9 ValMet). See text and Supplemental file 1
for statistics.
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factor binding, which may be also particularly important in
early development, when TFs are distributed in a concentration
gradient.57
Limitations of the study
A limitation of our study is that the assessment of hOCs relied
solely on maternal recall as the source of information about the
exposure. Unfortunately, this is a limitation shared by most of
the literature on obstetric complications.26 However, we believe
to have controlled potential bias in our protocol by using a
standardize questionnaire developed by previous published
reports,58 by employing the McNeil–Sj€ostr€om scale,27 and by
excluding from the analysis all the subjects with uncertain
information.
Another limitation of our study is represented by the analy-
sis of only a single region of the epigenome. Such approach was
chosen to detect a potential interaction between genome, epige-
nome and environment, which would have gone undetected in
a common whole-epigenome approach. By providing evidence
of an ‘epistatic’ interaction between genetic and epigenetic vari-
ation, our data raise the possibility that analyses on whole
genome and epigenome may give partial information, not tak-
ing into account that epigenetic changes can actually have
opposite meaning depending on genotype, and vice versa.
Conclusions
Our data display a dynamic interplay between genome, epige-
nome, and environment on prefrontal function and risk for
schizophrenia. Our main finding is the opposite relationship of
BDNF rs6265 methylation with phenotypes and environmental
factors relevant for schizophrenia in ValVal and ValMet sub-
jects. More specifically, DNA methylation of rs6265 is differen-
tially associated in ValVal and ValMet subjects with hOCs
exposure and with prefrontal behavior and activity. Further-
more, the results in healthy subjects, siblings and parents of
patients indicate that rs6265 methylation is associated with
genetic risk for schizophrenia differentially in the 2 genotypes
and that it can also be partially inherited. Although ambiguous
at a first glance, these results are consistent in showing that the
opposite methylation changes associated in the 2 genotypes
with a risk factor for schizophrenia, i.e., hOCs exposure, are
also associated with intermediate phenotypes for schizophrenia
and genetic risk for the disorder in a consistent way: specifi-
cally, in ValVal subjects enhanced methylation is associated
with hOCs exposure, impaired prefrontal cognition and ineffi-
ciency of prefrontal cortex, and methylation is also greater in
siblings and parents of patients compared with controls, while
in ValMet subjects blunted methylation is associated with
hOCs exposure, impaired prefrontal cognition and inefficiency
of prefrontal cortex, and methylation is lower in siblings and
parents of patients compared with controls.
These genotype-dependent in vivo findings suggest that
other molecular factors play a role. Indeed, rs6265 genotype
affects binding of transcription factors and the relationship
between DNA methylation and serum BDNF levels, so that the
methylation changes associated with hypoxia are also differen-
tially linked in both genotypes to BDNF levels. In this way,
environmentally-sensitive DNA methylation modulates the
effect of genetic variation, leading to risk phenotypes for com-
plex disorders. More in general, our results indicate that oppo-
site epigenetic, genotype-dependent changes may allow
developmental plasticity to “adapt” the organism to environ-
mental conditions, contributing to modulate complex pheno-
types above and beyond genetic variation.
Material and methods
Subjects, methylation analysis and genotyping
Two hundred and forty-four healthy subjects, 162 patients with
schizophrenia, 140 siblings and 217 parents of patients entered
the study, based on inclusion criteria and protocols specified
elsewhere.59 Briefly, all subjects were white Caucasians from
the region of Puglia and provided written informed consent.
The Structured Clinical Interview for DSM-IV was used to con-
firm diagnosis of schizophrenia for patients and to exclude any
Axis I psychiatric disorder for siblings, parents of patients and
healthy subjects. Exclusion criteria were presence of any neuro-
logical or medical condition, presence of head trauma with loss
of consciousness and drug abuse within the past 6 months. All
patients were on stable pharmacological treatment with anti-
psychotics. The Institutional Review Board of University of
Bari “Aldo Moro,” Bari (Italy), approved protocols and proce-
dures. DNA was extracted from PBMCs using QIAamp DNA
Blood Midi Kit (Qiagen, Valencia, CA, US) and bisulfite treated
as described previously.60 Methylation analysis was performed
with pyrosequencing, using primer sequences previously
reported36 and focused on CpG methylation sites in the region
of the BDNF gene containing rs6265. A consensus LINE-1
sequence was also analyzed to estimate global DNA methyla-
tion,60 in order to exclude any global effect (see Supplementary
Results for LINE-1 methylation results). Methylation was
expressed as percentage of methylated cytosines divided by the
sum of methylated and unmethylated cytosines (%5mC).61
SNP rs6265 was genotyped using the pyrosequencing assay
designed to interrogate percentage of methylation in this
region. In addition, genotypes were double-checked with direct
DNA sequencing, as previously described.62 Subjects with Met-
Met genotype were excluded from further analyses, after veri-
fied that, as expected, rs6265 methylation was around 0%. Lack
of methylation of the Met allele is consistent with absence of a
CpG site in this position, confirming the quality of bisulfite
treatment conversion of unmethylated Cytosine in Uracil/Thy-
mine. Supplemental file 1 contains information about the dif-
ferent samples analyzed.
Hypoxia-related Obstetric complications assessment
Obstetric Complications (OCs) refer to conditions occurring
not only during labor-delivery but also during pregnancy and
neonatal period. Specifically, OCs are here referred as “somatic
complications and conditions occurring during pregnancy,
labor-delivery and the neonatal period” experienced as an off-
spring with special focus on the CNS.27 We assessed OCs expo-
sure on the basis of interviews administered to mothers using a
standard questionnaire developed from other published
reports.58 OCs data were rated using the McNeil–Sj€ostr€om scale
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for obstetric complications,27 which assigns each OC a severity
score on a scale of 1–6. We determined OCs exposure based on
the presence of at least one serious OC. As in a previous
report,35 we adopted a strict definition of serious OC, i.e.,
McNeil-Sjostrom Scale score 5 . This score allowed identifica-
tion of individuals exposed to hypoxia-related (hOCs) poten-
tially harmful obstetric complications. The hOCs reported
included bleeding during pregnancy, maternal diabetes, mater-
nal infections, Rh incompatibility, adverse fetal position, cord
around neck, delivery problems, extended labor duration, use
of high forceps, emergency cesarean section, early gestational
age at birth and preterm birth, very low birth weight, respira-
tory distress at birth, and neonatal anomalies. Since a limitation
of our study is that the assessment of hOCs relied solely on
maternal recall as the source of information about the exposure,
we excluded from the analysis all the subjects with uncertain
information.
Working memory (WM) task
During fMRI, all subjects completed a blocked paradigm of the
N-back task.5 Briefly, ‘N-back’ refers to how far back in the
sequence of stimuli the subject had to recall. The stimuli con-
sisted of numbers (1–4) shown in random sequence and dis-
played at the points of a diamond-shaped box. There was a
visually paced motor task, which also served as a non-memory
guided control condition (0-back) that simply required subjects
to identify the stimulus currently seen. In the WM conditions,
the task required recollection of a stimulus seen 2 stimuli (2-
back) previously while continuing to encode additionally
incoming stimuli. All subjects were trained on the task before
the fMRI session. The stimuli of the task were organized in a
simple block design in which each block consisted of 8 alternat-
ing 0-back and 2-back WM condition lasting 4 m and 8 s. Stim-
uli were presented via a back-projection system and behavioral
responses were recorded through a fiber optic response box,
which allowed measurement of accuracy and reaction time for
each trial.
fMRI data acquisition
Blood oxygen level-dependent (BOLD) fMRI was performed on
a GE Signa 3T scanner (General Electric, Milwaukee, WI),
equipped with a standard quadrature head coil. A gradient-
echo planar imaging sequence (repetition time, 2000 ms; echo
time, 28 ms; 20 interleaved axial slices; thickness, 4 mm; gap,
1 mm; voxel size, 3.75 £ 3.75 £ 5; flip angle, 90; field of view,
24 cm; matrix, 64 £ 64) was used to acquire 120 volumes while
subjects performed the WM task. The first 4 scans were dis-
carded to allow for T1 equilibration effect.
fMRI data analysis
Analysis of the fMRI data was completed using Statistical
Parametric Mapping (SPM8; http://www.fil.ion.ucl.ac.uk/spm).
Images, for each subject, were realigned to the first volume in
the time series and movement parameters were extracted to
exclude subjects with excessive head motion (> 2 mm of trans-
lation, > 2 rotation). Images were then re-sampled to a 2 mm
isotropic voxel size, spatially normalized into a standard stereo-
tactic space (Montreal Institute on Neurology, MNI, template)
and smoothed using a 10 mm full-width half-maximum isotro-
pic Gaussian kernel to minimize noise and to account for resid-
ual inter-subject differences. A box car model convolved with
the hemodynamic response function (HRF) at each voxel was
modeled. In the first-level analysis, linear contrasts were com-
puted producing t statistical maps at each voxel for the 2-back
condition, assuming the 0-back condition as a baseline. All
individual contrast images were entered in a second level ran-
dom effects analysis. A multiple regression was performed
entering BDNF rs6265 genotype, BDNF rs6265 methylation
and hypoxia exposure scores as predictors. Because of our
strong a priori hypothesis about the dorsolateral prefrontal cor-
tex (DLPFC), we used a statistical threshold of P < 0.05, family
wise error small volume corrected using as volume of interest
the WFU_PickAtlas Brodmann’s areas in which significant
clusters were located (BA46).63 Because we did not have a priori
hypotheses regarding brain activity outside of DLPFC, we used
a statistical threshold of P < 0.05, FWE - corrected for whole-
brain comparisons.
PBMCs stimulation with Haloperidol
To evaluate the potential role of antipsychotic treatment on
BDNF rs6265 methylation, we assessed DNA methylation in
PBMCs of healthy subjects (11 ValVal, 6 ValMet) following in
vitro challenge with haloperidol. Briefly, blood (20 ml) was col-
lected and PBMCs were isolated by Ficoll density gradient
(ICN, Biomedical, Inc.), as previously described.5 After count-
ing, 3.5 £ 106 cells tube were resuspended in fresh RPMI 1640
medium (Gibco) (pH 7.5) with 15% FCS and HEPES (Sigma)
10 mM, and incubated at 37C with haloperidol 1 mM (Janssen
Pharmaceutical) for 0 (baseline), 2, and 5 h. Subsequently,
DNA was extracted and BDNF rs6265 methylation was ana-
lyzed with pyrosequencing.
BDNF expression measurement
In order to assess a potential relationship between methylation
and expression, we measured BDNF protein levels in serum,
which are likely derived by CNS sources and are altered in
patients with schizophrenia.41 Blood (10 ml) was collected
between 8:00 and 9:30 AM in anticoagulant-free tubes and
maintained at RT for 1 h, followed by 1 h at 4C. After centrifu-
gation at 2000 g for 10 min at 4C, serum samples were stored
up to 1 month at ¡20C and then analyzed in triplicate at the
same time. Sera were diluted 1:50 in sample buffer and total
BDNF was quantified using an ELISA kit (BDNF Emax immu-
noassay system, Promega) in a microplate reader (Anthos Lab-
tec Instrument) set at 450 nm. We also analyzed the
relationship between BDNF rs6265 methylation and mRNA
expression, in the same sample. BDNF mRNA levels were
assessed using the comparative CT method with b-actin as ref-
erence (control) gene, using TaqMan Gene Expression Assays
(Applied Biosystems, Cat. #4331182) specific for the following
transcripts: NM_170733.3 (Assay ID: Hs00380947_m1);
NM_170731.4 (hs00538277-m1); NM_170732.4 (hs00538278-
m1); NM_001709.4 (hs00156058-m1).
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Correlation of BDNF methylation in brain and PBMCs
We analyzed the correlation between BDNF rs6265 methylation
in PBMCs and in PFC in 7 homozygous (ValVal) and 9 hetero-
zygous (ValMet) mice described by Chen,64 which reproduce
the phenotypic hallmarks described in humans with the variant
allele. Mice were maintained on an inbred C57BL/6 back-
ground. The animals were housed under standard conditions
(12-h light/dark cycle with food and water available ad libitum)
and all studies were performed in adult mice. All animal han-
dling and experimental procedures were performed in accor-
dance with the EC (EEC Council Directive 86/609 1987), the
Italian legislation on animal experimentation (Decreto Legisla-
tivo 116/92), and the National Institutes of Health Guide for
the Care and Use of Laboratory Animals. All efforts were made
to minimize animal suffering and to reduce the number of ani-
mals used. Samples of trunk blood from each mouse were col-
lected in tubes containing sodium citrate and then rapidly
processed for DNA analysis (see below), whereas frontal lobes
were dissected, frozen on dry ice and stored for further analyses
at ¡80C. Genomic DNA from whole plasma was extracted
using ReliaPrepTM Blood gDNA Miniprep System kit (Prom-
ega, Italy), while DNA from brain tissue was isolated using phe-
nol/chloroform extraction method. Analysis of mice BDNF
rs6265 methylation was performed with pyrosequencing, as
described in humans.
Quantitative chromatin immunoprecipitation assay (ChIP)
Given the differential genotype-dependent relationship
between rs6265 methylation and BDNF expression, we per-
formed a ChIP experiment in order to investigate whether the
BDNF region containing rs6265 can bind transcription factors
and proteins in a genotype-dependent manner. We selected
DNA-binding proteins based on bioinformatics predictions
and previous research, as described in the main text. Bioinfor-
matics tools (www.genomatix.de) suggest how rs6265 genetic
variation can affect binding of transcription factors so that the
G(Val)/A(Met) substitution abolishes a potential binding site
for HIF1a, BHLHB2 (also known as DEC1 or BHLHE40), and
CREB while it creates a binding site for MITF. PBMCs were
isolated from 20 healthy individuals (11 ValVal, 9 ValMet), as
previously described.5 Protein bound to DNA was cross-linked
by PBMCs with 1% formaldehyde at room temperature, stop-
ping the reaction 10 min later with the addition of 2.5 M
glycine to a final concentration of 125 mM, followed by 5 min
incubation at room temperature. ChIP assays were performed
using the EpiQuikTM chromatin immunoprecipitation kit from
Epigentek Group Inc. (Brooklyn, NY) starting from »0.5 £ 106
PBMC cells. Antibodies used for Protein-DNA immunoprecip-
itation were: anti-HIF1a (antibody provided from Dr. C. W.
Pugh, Center for Cellular & Molecular Physiology, University
of Oxford, Oxford, United Kingdom65), anti-MITF and anti-
GADD45B (Aviva System Biology, San Diego, CA), anti-
BHLHB2/DEC1 (Bethyl Laboratories, Inc. Montgomery, TX
USA), anti-CREB (Merck Millipore Headquarters, Billerica,
MA), and normal mouse IgG as a negative control antibody.
DNA from these samples was subjected to quantitative PCR
analyses, using Power SYBR Green PCR Master Mix (Life
Technologies Corporation, Carlsbad, California) in a Chromo4
Real Time thermocycler (BIORAD). Amplification of the
BDNF promoters fragment was performed using the primers:
pBDNFf (forward) 50-CCAAGGCAGGTTCAAGAGG-30 and
pBDNFr (reverse) 50-CGAACTTTCTGGTCCTCATCC-30
amplifying a 90 bp fragment including rs6265 SNP. The quanti-
tative PCR conditions were: 95C for 10 min followed by 40
cycles of 95C for 15 s, 62C for 1 min. All PCR signals from
immunoprecipitated DNA were normalized to PCR signals from
non-immunoprecipitated input DNA. The signals obtained by
precipitation with the control IgG were subtracted from the sig-
nals obtained with the specific antibodies. Results are expressed
as percentage of the input.66 Calculations were performed using
the average values of at least 3 independent experiments.
Statistical analysis
All statistical analyses—except for fMRI—were performed in
the R environment. We used ANOVAs in order to analyze the
effect of rs6265 genotype on methylation and on DNA-binding
of proteins and transcription factors; we used ANCOVAs (with
age and sex as covariates) to analyze the interaction between
rs6265 genotype and hOCs on methylation, and the relation-
ship between rs6265 genotype, methylation and schizophrenia
risk and diagnosis. To assess in vitro effects of the challenge
with haloperidol on rs6265 methylation, we performed an
ANOVA with rs6265 genotype and incubation time with halo-
peridol as independent categorical variables (0 h/basal, 2 h, 5 h)
and rs6265 methylation changes as dependent variable. Herita-
bility of rs6265 methylation was estimated from the regression
slope of offspring methylation on the average methylation of
the parents.67 We used multiple regressions in order to analyze
the interaction between rs6265 genotype, methylation and
hOCs on WM accuracy; the interaction between rs6265 geno-
type and methylation on BDNF levels. Finally, we used Spear-
man correlation in order to analyze the relationship between
rs6265 methylation in PBMCs and in PFC in mice. Statistical
models for the analyses are also reported in Supplemental file 1.
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